Drug Profile
Vitespen
Alternative Names: Cancer vaccine heat shock protein peptide complex-96 - Agenus; Cancer vaccine HSPPC-96; G-100; G-200; Heat shock protein peptide complex 96 cancer vaccine - Agenus; Heat-shock protein-based vaccine; HSPPC-96; NP-150; Oncophage; Prophage series G-100 vaccine; Prophage series G-200 vaccine; Prophage™ heat shock protein-based autologous vaccineLatest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator Fordham University; Mount Sinai School of Medicine
- Developer Agenus; University of Texas Health Science Center at Houston
- Class Antineoplastics; Cancer vaccines; Heat shock proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Marketed Renal cell carcinoma
- Phase II Glioma; Malignant melanoma
- No development reported Brain cancer; Colorectal cancer; Gastric cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer
- Discontinued Chronic myeloid leukaemia; Leukaemia; Sarcoma
Most Recent Events
- 01 May 2023 The Alliance for Clinical Trials in Oncology terminates a phase II trial for Glioma/GBM (Combination therapy) in USA (Intradermal, Infusion) (NCT01814813)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Brain-cancer(In children, In infants) in USA (Intradermal)
- 17 Jan 2017 Agenus and National Cancer Institute plan a phase II trial of vitespen and pembrolizumab for Glioma (Combination therapy, Newly diagnosed) in USA